Exacerbación aguda de la enfermedad pulmonar obstructiva crónica

Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007;131:696-704.Resumen external link opens in a new window

Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clini Microbiol Infect. 2011;17(suppl 6):E1-E59.Texto completo external link opens in a new windowResumen external link opens in a new window

Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497-1505.Resumen external link opens in a new window

Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106:91-101.Resumen external link opens in a new window

Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(12):CD010257.Texto completo external link opens in a new windowResumen external link opens in a new window

Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13-e64.Resumen external link opens in a new window

Celli BR, MacNee W, Agusti A, et al; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.Texto completo external link opens in a new windowResumen external link opens in a new window

Tang CY, Blackstock FC, Clarence M, et al. Early rehabilitation exercise program for inpatients during an acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. J Cardiopulm Rehabil Prev. 2012;32:163-169.Resumen external link opens in a new window

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication]Texto completo external link opens in a new window

2. Bastin AJ, Starling L, Ahmed R, et al. High prevalence of undiagnosed and severe chronic obstructive pulmonary disease at first hospital admission with acute exacerbation. Chron Respir Dis. 2010;7:91-97.Resumen external link opens in a new window

3. Hanania NA, Marciniuk DD. A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest. 2011;140:565-566.Texto completo external link opens in a new windowResumen external link opens in a new window

4. Jemal A, Ward E, Hao Y. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294:1255-1259.Texto completo external link opens in a new windowResumen external link opens in a new window

5. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-773.Resumen external link opens in a new window

6. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100:115-122.Resumen external link opens in a new window

7. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741-750.Resumen external link opens in a new window

8. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875-1881.Resumen external link opens in a new window

9. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax. 2000;55:789-794.Texto completo external link opens in a new windowResumen external link opens in a new window

10. de Torres JP, Casanova C, Hernandez C, et al. Gender and COPD in patients attending a pulmonary clinic. Chest. 2005;128:2012-2016.Resumen external link opens in a new window

11. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608-1613.Resumen external link opens in a new window

12. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-1422.Resumen external link opens in a new window

13. Rodriguez-Roisin R. COPD exacerbations.5: management. Thorax. 2006;61:535-544.Resumen external link opens in a new window

14. O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax. 2006;61:354-361.Resumen external link opens in a new window

15. Barberà JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1997;10:1285-1291.Texto completo external link opens in a new windowResumen external link opens in a new window

16. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007;131:696-704.Resumen external link opens in a new window

17. Spencer S, Jones PW; GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589-593.Texto completo external link opens in a new windowResumen external link opens in a new window

18. Xu W, Collet JP, Shapiro S, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J. 2010;35:1022-1030.Resumen external link opens in a new window

19. Rabe KF, Fabbri LM, Vogelmeier C, et al. Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest. 2013;143:711-719.Resumen external link opens in a new window

20. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2689-2697.Resumen external link opens in a new window

21. Ai-Ping C, Lee KH, Lim TK. In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest. 2005;128:518-524.Resumen external link opens in a new window

22. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-852.Resumen external link opens in a new window

23. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995;274:1852-1857.Resumen external link opens in a new window

24. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925-931.Texto completo external link opens in a new windowResumen external link opens in a new window

25. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136:376-380.Resumen external link opens in a new window

26. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091-1097.Resumen external link opens in a new window

27. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003;97:115-122.Resumen external link opens in a new window

28. Sapey E, Stockley RA. COPD exacerbations.2: aetiology. Thorax. 2006;61:250-258.Resumen external link opens in a new window

29. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653.Texto completo external link opens in a new windowResumen external link opens in a new window

30. Anzueto A. Primary care management of chronic obstructive pulmonary disease to reduce exacerbations and their consequences. Am J Med Sci. 2010;340:309-318.Resumen external link opens in a new window

31. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clini Microbiol Infect. 2011;17(suppl 6):E1-E59.Texto completo external link opens in a new windowResumen external link opens in a new window

32. Lieberman D, Lieberman D, Ben-Yaakov M, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis. 2001;40:95-102.Resumen external link opens in a new window

33. Greenberg SB, Allen M, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:167-173.Resumen external link opens in a new window

34. Beckham JD, Cadena A, Lin J, et al. Respiratory viral infections in patients with chronic obstructive pulmonary disease. J Infect. 2005;50:322-330.Resumen external link opens in a new window

35. Martinello RA, Esper F, Weibel C, et al. Human metapneumovirus and exacerbations of chronic obstructive pulmonary disease. J Infect. 2006;53:248-254.Resumen external link opens in a new window

36. Dennis RJ, Maldonado D, Norman S, et al. Woodsmoke exposure and risk for obstructive airways disease among women. Chest. 1996;109:115-119.Resumen external link opens in a new window

37. Sunyer J, Saez M, Murillo C, et al. Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study. Am J Epidemiol. 1993;137:701-705.Resumen external link opens in a new window

38. Jones JG, Minty BD, Lawler P, et al. Increased alveolar epithelial permeability in cigarette smokers. Lancet. 1980;1:66-68.Resumen external link opens in a new window

39. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001;14:336-363.Texto completo external link opens in a new windowResumen external link opens in a new window

40. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269-280.Resumen external link opens in a new window

41. Stockley RA. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin. 2009;25:1235-1245.Resumen external link opens in a new window

42. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355-2365.Resumen external link opens in a new window

43. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest. 2000;117(suppl 2):10S-14S.Resumen external link opens in a new window

44. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709-721.Resumen external link opens in a new window

45. Lougheed DM, Webb KA, O'Donnell DE. Breathlessness during induced lung hyperinflation in asthma: the role of the inspiratory threshold load. Am J Respir Crit Care Med. 1995;152:911-920.Resumen external link opens in a new window

46. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-1276.Resumen external link opens in a new window

47. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31:742-750.Texto completo external link opens in a new windowResumen external link opens in a new window

48. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:967-975.Resumen external link opens in a new window

49. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743-1748.Resumen external link opens in a new window

50. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114-1121.Resumen external link opens in a new window

51. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370:786-796.Resumen external link opens in a new window

52. Hurst JR, Wedzicha JA. The biology of a chronic obstructive pulmonary disease exacerbation. Clin Chest Med. 2007;28:525-536.Resumen external link opens in a new window

53. Giacomini M, DeJean D, Simeonov D, et al. Experiences of living and dying with COPD: a systematic review and synthesis of the qualitative empirical literature. Ont Health Technol Assess Ser. 2012;12:1-47.Texto completo external link opens in a new windowResumen external link opens in a new window

54. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s-53s.Resumen external link opens in a new window

55. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-1138.Texto completo external link opens in a new windowResumen external link opens in a new window

56. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131:20-28.Resumen external link opens in a new window

57. Foreman MG, DeMeo DL, Hersh CP, et al. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J. 2007;30:1124-1130.Resumen external link opens in a new window

58. Soler N, Agusti C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007;62:29-35.Resumen external link opens in a new window

59. Wilkinson TM, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006;129:317-324.Resumen external link opens in a new window

60. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:356-361.Resumen external link opens in a new window

61. Caramori G, Adcock IM, Papi A. Clinical definition of COPD exacerbations and classification of their severity. South Med J. 2009;102:277-282.Resumen external link opens in a new window

62. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465-471.Resumen external link opens in a new window

63. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.Resumen external link opens in a new window

64. Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res. 2007;8:30.Texto completo external link opens in a new windowResumen external link opens in a new window

65. Terada K, Muro S, Sato S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax. 2008;63:951-955.Resumen external link opens in a new window

66. Terada K, Muro S, Ohara T, et al. Abnormal swallowing reflex and COPD exacerbations. Chest. 2010;137:326-332.Resumen external link opens in a new window

67. Seemungal TA, Harper-Owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 2000;16:677-683.Texto completo external link opens in a new windowResumen external link opens in a new window

68. Falsey AR, Formica MA, Hennessey PA, et al. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:639-643.Resumen external link opens in a new window

69. Hurst JR, Donaldson GC, Wilkinson TM, et al. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J. 2005;26:846-852.Texto completo external link opens in a new windowResumen external link opens in a new window

70. Hogg JC. Role of latent viral infections in chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med. 2001;164:S71-S75.Resumen external link opens in a new window

71. Anderson HR, Spix C, Medina S, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J. 1997;10:1064-1071.Resumen external link opens in a new window

72. Yang CY, Chen CC, Chen CY, et al. Air pollution and hospital admissions for asthma in a subtropical city: Taipei, Taiwan. J Toxicol Environ Health A. 2007;70:111-117.Resumen external link opens in a new window

73. Pope CA, 3rd, Kanner RE. Acute effects of PM10 pollution on pulmonary function of smokers with mild to moderate chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;147:1336-1340.Resumen external link opens in a new window

74. Faustini A, Stafoggia M, Colais P, et al. Air pollution and multiple acute respiratory outcomes. Eur Respir J. 2013;42:304-313.Texto completo external link opens in a new windowResumen external link opens in a new window

75. Diederen BM, van der Valk PD, Kluytmans JA, et al. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;30:240-244.Resumen external link opens in a new window

76. Blasi F, Damato S, Cosentini R, et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax. 2002;57:672-676.Resumen external link opens in a new window

77. Seemungal TA, Wedzicha JA, MacCallum PK, et al. Chlamydia pneumoniae and COPD exacerbation. Thorax. 2002;57:1087-1088.Resumen external link opens in a new window

78. Donaldson GC, Seemungal T, Jeffries DJ, et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J. 1999;13:844-849.Resumen external link opens in a new window

79. Chen CZ, Ou CY, Yu CH, et al. Comparison of global initiative for chronic obstructive pulmonary disease 2013 classification and body mass index, airflow obstruction, dyspnea, and exacerbations index in predicting mortality and exacerbations in elderly adults with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2015;63:244-250.Resumen external link opens in a new window

80. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497-1505.Resumen external link opens in a new window

81. Thabane M; COPD Working Group. Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-50.Texto completo external link opens in a new windowResumen external link opens in a new window

82. Au DH, Bryson CL, Chien JW, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2009;24:457-463.Texto completo external link opens in a new windowResumen external link opens in a new window

83. Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.Texto completo external link opens in a new windowResumen external link opens in a new window

84. McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119:1190-1209.Resumen external link opens in a new window

85. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130:397-403.Resumen external link opens in a new window

86. Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004;125:2011-2020.Resumen external link opens in a new window

87. Sehatzadeh S. Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review. Ont Health Technol Assess Ser. 2012;12:1-64.Texto completo external link opens in a new windowResumen external link opens in a new window

88. OHTAC COPD Collaborative. Chronic obstructive pulmonary disease (COPD) evidentiary framework. Ont Health Technol Assess Ser. 2012;12:1-97.Texto completo external link opens in a new windowResumen external link opens in a new window

89. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006;61:189-195.Resumen external link opens in a new window

90. Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jan 24;1:CD001390.Texto completo external link opens in a new windowResumen external link opens in a new window

91. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618-1623.Resumen external link opens in a new window

92. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1087-1092.Resumen external link opens in a new window

93. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.Resumen external link opens in a new window

94. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317-326.Resumen external link opens in a new window

95. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-965.Resumen external link opens in a new window

96. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.Texto completo external link opens in a new windowResumen external link opens in a new window

97. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.Texto completo external link opens in a new windowResumen external link opens in a new window

98. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.Texto completo external link opens in a new windowResumen external link opens in a new window

99. Tashkin DP. Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium. Int J Chron Obstruct Pulmon Dis. 2010;5:41-53.Texto completo external link opens in a new windowResumen external link opens in a new window

100. Halpin D, Menjoge S, Viel K. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J. 2009;18:106-113.Resumen external link opens in a new window

101. Cooper CB, Anzueto A, Decramer M, et al. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Int J Chron Obstruct Pulmon Dis. 2011;6:269-275.Texto completo external link opens in a new windowResumen external link opens in a new window

102. Morice AH, Celli B, Kesten S, et al. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med. 2010;104:1659-1667.Resumen external link opens in a new window

103. Van den BA, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med. 2010;10:50.Texto completo external link opens in a new windowResumen external link opens in a new window

104. Wang J, Nie B, Xiong W, et al. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther. 2012;37:204-211.Resumen external link opens in a new window

105. Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Resp Care. 2011;56:477-487.Texto completo external link opens in a new windowResumen external link opens in a new window

106. Decramer ML, Hanania NA, Lötvall JO, et al. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:53-64.Texto completo external link opens in a new windowResumen external link opens in a new window

107. Mahler DA, Buhl R, Lawrence D, et al. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther. 2013;26:348-355.Resumen external link opens in a new window

108. Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(10):CD010177.Texto completo external link opens in a new windowResumen external link opens in a new window

109. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093-1103.Resumen external link opens in a new window

110. Vogelmeier C, Fabbri LM, Rabe KF, et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients. Respir Med. 2013;107:75-83.Resumen external link opens in a new window

111. Beasley R, Singh S, Loke YK, et al. Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ. 2012;345:e7390.Resumen external link opens in a new window

112. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-479.Resumen external link opens in a new window

113. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140:68-75.Texto completo external link opens in a new windowResumen external link opens in a new window

114. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.Texto completo external link opens in a new windowResumen external link opens in a new window

115. van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24:666-672.Resumen external link opens in a new window

116. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12:55.Texto completo external link opens in a new windowResumen external link opens in a new window

117. Frampton JE. Aclidinium: in chronic obstructive pulmonary disease. Drugs. 2012;72:1999-2011.Resumen external link opens in a new window

118. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(9):CD010509.Texto completo external link opens in a new windowResumen external link opens in a new window

119. Wang J, Jin D, Zuo P, et al. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology. 2011;16:350-358.Resumen external link opens in a new window

120. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199-209.Resumen external link opens in a new window

121. National Horizon Scanning Centre. Umeclidinium and vilanterol for chronic obstructive pulmonary disease. February 2012. http://www.hsc.nihr.ac.uk (last accessed 28 December 2015).Texto completo external link opens in a new window

122. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484-1494.Texto completo external link opens in a new windowResumen external link opens in a new window

123. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-1546.Texto completo external link opens in a new windowResumen external link opens in a new window

124. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297-1303.Texto completo external link opens in a new windowResumen external link opens in a new window

125. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902-1909.Texto completo external link opens in a new windowResumen external link opens in a new window

126. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545-555.Texto completo external link opens in a new windowResumen external link opens in a new window

127. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59-65.Resumen external link opens in a new window

128. Spencer S, Karner C, Cates CJ, et al. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(12):CD007033.Texto completo external link opens in a new windowResumen external link opens in a new window

129. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.Resumen external link opens in a new window

130. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912-919.Texto completo external link opens in a new windowResumen external link opens in a new window

131. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008;102:1099-1108.Resumen external link opens in a new window

132. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332-338.Resumen external link opens in a new window

133. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009;6:320-329.Resumen external link opens in a new window

134. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60:480-487.Texto completo external link opens in a new windowResumen external link opens in a new window

135. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285-1294.Texto completo external link opens in a new windowResumen external link opens in a new window

136. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 May 31;(5):CD007891.Texto completo external link opens in a new windowResumen external link opens in a new window

137. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34:641-647.Texto completo external link opens in a new windowResumen external link opens in a new window

138. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:189-195.Texto completo external link opens in a new windowResumen external link opens in a new window

139. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139:505-512.Texto completo external link opens in a new windowResumen external link opens in a new window

140. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(3):CD010115.Texto completo external link opens in a new windowResumen external link opens in a new window

141. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008;102:479-487.Resumen external link opens in a new window

142. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68:1975-2000.Resumen external link opens in a new window

143. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19-26.Resumen external link opens in a new window

144. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741-750.Resumen external link opens in a new window

145. Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD. 2011;8:206-243.Resumen external link opens in a new window

146. Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(9):CD009039.Texto completo external link opens in a new windowResumen external link opens in a new window

147. Rojas-Reyes MX, García Morales OM, Dennis RJ, Karner C. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Jun 6;(6):CD008532.Texto completo external link opens in a new windowResumen external link opens in a new window

148. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009;29:891-905.Resumen external link opens in a new window

149. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009;136:1029-1038.Resumen external link opens in a new window

150. Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106:91-101.Resumen external link opens in a new window

151. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365: 689-698.Resumen external link opens in a new window

152. Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013;107:637-648.Resumen external link opens in a new window

153. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10.Texto completo external link opens in a new windowResumen external link opens in a new window

154. Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J. 2009;34:1066-1071.Texto completo external link opens in a new windowResumen external link opens in a new window

155. Rennard SI, Schachter N, Strek M, et al. Cilomilast for COPD:results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006;129:56-66.Resumen external link opens in a new window

156. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366:563-571.Resumen external link opens in a new window

157. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.Resumen external link opens in a new window

158. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62:1373-1378.Resumen external link opens in a new window

159. Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest. 2009;136:734-743.Resumen external link opens in a new window

160. Lee JS, Park DA, Hong Y, et al. Systematic review and meta-analysis of prophylactic antibiotics in COPD and/or chronic bronchitis. Int J Tuberc Lung Dis. 2013;17:153-162.Resumen external link opens in a new window

161. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189:1503-1508.Texto completo external link opens in a new windowResumen external link opens in a new window

162. Rennard S, Calverley PM, Goehring PMA, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast—the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.Texto completo external link opens in a new windowResumen external link opens in a new window

163. Taegtmeyer AB, Leuppi JD, Kullak-Ublick GA. Roflumilast: a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD. Swiss Med Wkly. 2012;142:w13628.Resumen external link opens in a new window

164. Davies L, Calverley PM. The evidence for the use of oral mucolytic agents in chronic obstructive pulmonary disease (COPD). Br Med Bull. 2010;93:217-227.Texto completo external link opens in a new windowResumen external link opens in a new window

165. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(7):CD001287.Texto completo external link opens in a new windowResumen external link opens in a new window

166. Kueppers F. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Curr Med Res Opin. 2011;27:579-588.Resumen external link opens in a new window

167. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.Texto completo external link opens in a new windowResumen external link opens in a new window

168. Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.Texto completo external link opens in a new windowResumen external link opens in a new window

169. Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev. 2010;(10):CD001958.Resumen external link opens in a new window

170. Teo E, Lockhart K, Purchuri SN, et al. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jun 19;6:CD010010.Texto completo external link opens in a new windowResumen external link opens in a new window

171. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370:2201-2210.Texto completo external link opens in a new windowResumen external link opens in a new window

172. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(suppl 2):398S-401S.Resumen external link opens in a new window

173. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med. 2004;98:99-107.Resumen external link opens in a new window

174. Quon BS, Gan WQ, Sin DD, et al. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008;133:756-766.Resumen external link opens in a new window

175. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017 Oct 12;10:CD007498.Texto completo external link opens in a new windowResumen external link opens in a new window

176. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581-586.Resumen external link opens in a new window

177. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638-1645.Resumen external link opens in a new window

178. Gompertz S, O'Brien C, Bayley DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:1112-1119.Texto completo external link opens in a new windowResumen external link opens in a new window

179. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128:2640-2646.Resumen external link opens in a new window

180. Lim BL, Kelly AM. A meta-analysis on the utility of peripheral venous blood gas analyses in exacerbations of chronic obstructive pulmonary disease in the emergency department. Eur J Emerg Med. 2010;17:246-248.Resumen external link opens in a new window

181. British Thoracic Society. BTS Guideline for oxygen use in healthcare and emergency settings. October 2017 [internet publication]Texto completo external link opens in a new windowResumen external link opens in a new window

182. Brekke PH, Omland T, Smith P, et al. Underdiagnosis of myocardial infarction in COPD - Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med. 2008;102:1243-1247.Resumen external link opens in a new window

183. Gelow JM, Fang JC. Update in the approach to and management of heart failure. South Med J. 2006;99:1346-1355.Resumen external link opens in a new window

184. Doust J, Lehman R, Glasziou P. The role of BNP testing in heart failure. Am Fam Physician. 2006;74:1893-1898.Resumen external link opens in a new window

185. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004 Feb 12;350(7):647-54.Texto completo external link opens in a new windowResumen external link opens in a new window

186. Dewan NA. COPD exacerbations: to X-ray or not to X-ray. Chest. 2002;122:1118-1121.Resumen external link opens in a new window

187. Emerman CL, Cydulka RK. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med. 1993;22:680-684Resumen external link opens in a new window

188. Sherman S, Skoney JA, Ravikrishnan KP. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. Arch Intern Med. 1989;149:2493-2496.Resumen external link opens in a new window

189. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest. 2002;122:1264-1270.Resumen external link opens in a new window

190. Slater A, Goodwin M, Anderson KE, et al. COPD can mimic the appearance of pneumothorax on thoracic ultrasound. Chest. 2006;129:545-550.Resumen external link opens in a new window

191. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006 Mar 21;144(6):390-6.Resumen external link opens in a new window

192. Robinson TD, Freiberg DB, Regnis JA, et al. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1524-1529.Resumen external link opens in a new window

193. Santos C, Ferrer M, Roca J, et al. Pulmonary gas exchange response to oxygen breathing in acute lung injury. Am J Respir Crit Care Med. 2000;161:26-31.Resumen external link opens in a new window

194. Hanson CW, 3rd, Marshall BE, Frasch HF, et al. Causes of hypercarbia with oxygen therapy in patients with chronic obstructive pulmonary disease. Crit Care Med. 1996;24:23-28.Resumen external link opens in a new window

195. Austin MA, Wills KE, Blizzard L, et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462.Texto completo external link opens in a new windowResumen external link opens in a new window

196. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340:1941-1947.Resumen external link opens in a new window

197. Walters JA, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(9):CD001288.Texto completo external link opens in a new windowResumen external link opens in a new window

198. Walters JA, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(3):CD005374.Resumen external link opens in a new window

199. de Jong YP, Uil SM, Grotjohan HP, et al. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 2007;132:1741-1747.Resumen external link opens in a new window

200. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(12):CD006897.Texto completo external link opens in a new windowResumen external link opens in a new window

201. Abroug F, Ouanes-Besbes L, Fkih-Hassen M, et al. Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation. Eur Respir J. 2014;43:717-724.Resumen external link opens in a new window

202. Gaude GS, Nadagouda S. Nebulized corticosteroids in the management of acute exacerbation of COPD. Lung India. 2010;27:230-235.Texto completo external link opens in a new windowResumen external link opens in a new window

203. Ram FS. Use of theophylline in chronic obstructive pulmonary disease: examining the evidence. Curr Opin Pulm Med. 2006;12:132-139.Resumen external link opens in a new window

204. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006;11:603-610.Resumen external link opens in a new window

205. Barr RG, Rowe BH, Camargo CA, Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ. 2003;327:643.Texto completo external link opens in a new windowResumen external link opens in a new window

206. Osadnik CR, McDonald CF, Miller BR, et al. The effect of positive expiratory pressure (PEP) therapy on symptoms, quality of life and incidence of re-exacerbation in patients with acute exacerbations of chronic obstructive pulmonary disease: a multicentre, randomised controlled trial. Thorax. 2014;69:137-143.Resumen external link opens in a new window

207. Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med. 2001;134:600-620.Resumen external link opens in a new window

208. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 1995;273:957-960.Resumen external link opens in a new window

209. Llor C, Moragas A, Hernández S, et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:716-723.Texto completo external link opens in a new windowResumen external link opens in a new window

210. Veterans Affairs/Department of Defense. VA/DoD clinical practice guideline: the management of chronic obstructive pulmonary disease. December 2014. http://www.healthquality.va.gov/ (last accessed 28 December 2015).Texto completo external link opens in a new window

211. Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(12):CD010257.Texto completo external link opens in a new windowResumen external link opens in a new window

212. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953-964.Resumen external link opens in a new window

213. Wilson R, Schentag JJ, Ball P, et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002;24:639-652.Resumen external link opens in a new window

214. Wilson R, Jones P, Schaberg T, et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax. 2006;61:337-342.Resumen external link opens in a new window

215. Grossman RF, Ambrusz ME, Fisher AC, et al. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. Clin Ther. 2006;28:1175-1180.Resumen external link opens in a new window

216. Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J. 2007;29:1127-1137.Resumen external link opens in a new window

217. Dimopoulos G, Siempos, II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a meta-analysis of randomized controlled trials. Chest. 2007;132:447-455.Resumen external link opens in a new window

218. Keenan SP, Kernerman PD, Cook DJ, et al. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta-analysis. Crit Care Med. 1997;25:1685-1692.Resumen external link opens in a new window

219. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333:817-822.Resumen external link opens in a new window

220. Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med. 1995;151:1799-1806.Resumen external link opens in a new window

221. Osadnik CR, Tee VS, Carson-Chahhoud KV, et al. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jul 13;7:CD004104.Texto completo external link opens in a new windowResumen external link opens in a new window

222. Keenan SP, Sinuff T, Burns KE, et al. Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting. CMAJ. 2011;183:E195-214.Texto completo external link opens in a new windowResumen external link opens in a new window

223. McCurdy BR. Noninvasive positive pressure ventilation for acute respiratory failure patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-102.Texto completo external link opens in a new windowResumen external link opens in a new window

224. Koh Y. Ventilatory management in patients with chronic airflow obstruction. Crit Care Clin. 2007;23:169-181.Resumen external link opens in a new window

225. Chandra D, Stamm JA, Taylor B, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med. 2012;185:152-159.Texto completo external link opens in a new windowResumen external link opens in a new window

226. Breen D, Churches T, Hawker F, et al. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. Thorax. 2002;57:29-33.Texto completo external link opens in a new windowResumen external link opens in a new window

227. Udwadia ZF, Santis GK, Steven MH, et al. Nasal ventilation to facilitate weaning in patients with chronic respiratory insufficiency. Thorax. 1992;47:715-718.Resumen external link opens in a new window

228. Perkins GD, Olasveengen TM, Maconochie I, et al. European Resuscitation Council guidelines for resuscitation: 2017 update. Resuscitation. 2018 Feb;123:43-50.Resumen external link opens in a new window

229. Colquhoun MC, Handley AJ, Evans TR, eds. ABC of resuscitation. 5th ed. Wiley-Blackwell; 2004.

230. Soar J, Nolan JP, Böttiger BW, et al. European Resuscitation Council guidelines for resuscitation 2015: Section 3. Adult advanced life support. Resuscitation. 2015;95:100-147.Resumen external link opens in a new window

231. Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010;182:890-896.Resumen external link opens in a new window

232. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13-e64.Resumen external link opens in a new window

233. British Thoracic Society. BTS guideline on pulmonary rehabilitation in adults. September 2013. https://www.brit-thoracic.org.uk (last accessed 28 December 2015).Texto completo external link opens in a new window

234. Zanotti E, Felicetti G, Maini M, et al. Peripheral muscle strength training in bed-bound patients with COPD receiving mechanical ventilation: effect of electrical stimulation. Chest. 2003;124:292-296.Resumen external link opens in a new window

235. Troosters T, Probst VS, Crul T, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:1072-1077.Resumen external link opens in a new window

236. Reid WD, Yamabayashi C, Goodridge D, et al. Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews. Int J Chron Obstruct Pulmon Dis. 2012;7:297-320.Texto completo external link opens in a new windowResumen external link opens in a new window

237. Man WD, Polkey MI, Donaldson N, et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ. 2004;329:1209.Texto completo external link opens in a new windowResumen external link opens in a new window

238. Seymour JM, Moore L, Jolley CJ, et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010;65:423-428.Resumen external link opens in a new window

239. Marciniuk DD, Brooks D, Butcher S, et al. Canadian Thoracic Society COPD Committee Expert Working Group. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can Respir J. 2010;17:159-168.Resumen external link opens in a new window

240. Clini EM, Crisafulli E, Costi S, et al. Effects of early inpatient rehabilitation after acute exacerbation of COPD. Respir Med. 2009;103:1526-1531.Resumen external link opens in a new window

241. Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Dec 8;12:CD005305.Texto completo external link opens in a new windowResumen external link opens in a new window

242. Puhan MA, Scharplatz M, Troosters T, et al. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality--a systematic review. Respir Res. 2005;6:54.Texto completo external link opens in a new windowResumen external link opens in a new window

243. Greening NJ, Williams JE, Hussain SF, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ. 2014;349:g4315.Texto completo external link opens in a new windowResumen external link opens in a new window

244. Turner MO, Patel A, Ginsburg S, et al. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med. 1997;157:1736-1744.Resumen external link opens in a new window

245. Stevenson NJ, Walker PP, Costello RW, et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:1510-1516.Resumen external link opens in a new window

246. Holland A, Smith F, Penny K, et al. Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units. Cochrane Database Syst Rev. 2013;(6):CD008863.Texto completo external link opens in a new windowResumen external link opens in a new window

247. Karpel JP, Pesin J, Greenberg D, et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest. 1990;98:835-839.Resumen external link opens in a new window

248. Celli BR, MacNee W, Agusti A, et al; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.Texto completo external link opens in a new windowResumen external link opens in a new window

249. Emerman CL, Cydulka RK. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med. 1997;29:474-478.Resumen external link opens in a new window

250. Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax. 1995;50:834-837.Resumen external link opens in a new window

251. Patrick DM, Dales RE, Stark RM, et al. Severe exacerbations of COPD and asthma: incremental benefit of adding ipratropium to usual therapy. Chest. 1990;98:295-297.Resumen external link opens in a new window

252. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309:2223-2231.Texto completo external link opens in a new windowResumen external link opens in a new window

253. Zheng J, Lin J, Zhou X, et al. Nebulized budesonide in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD): a randomized, double blind, double dummy, parallel controlled, multicenter trial. Chest. 2011;140:526A.Texto completo external link opens in a new window

254. Alía I, de la Cal MA, Esteban A, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med. 2011;171:1939-1946.Texto completo external link opens in a new windowResumen external link opens in a new window

255. Osadnik CR, McDonald CF, Jones AP, et al. Airway clearance techniques for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(3):CD008328.Texto completo external link opens in a new windowResumen external link opens in a new window

256. Hill K, Patman S, Brooks D. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review. Chron Respir Dis. 2010;7:9-17.Resumen external link opens in a new window

257. Cross J, Elender F, Barton G, et al. A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX). Health Technol Assess. 2010;14:1-147, iii-iv.Resumen external link opens in a new window

258. Tang CY, Taylor NF, Blackstock FC. Chest physiotherapy for patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease (COPD): a systematic review. Physiotherapy. 2010;96:1-13.Resumen external link opens in a new window

259. Agusti AG, Carrera M, Barbe F, et al. Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1999;14:934-939.Resumen external link opens in a new window

260. Puhan MA, Vollenweider D, Steurer J, et al. Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. BMC Med. 2008;6:28.Texto completo external link opens in a new windowResumen external link opens in a new window

261. El Moussaoui R, Roede BM, Speelman P, et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax. 2008;63:415-422.Texto completo external link opens in a new windowResumen external link opens in a new window

262. Falagas ME, Avgeri SG, Matthaiou DK, et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008;62:442-450.Texto completo external link opens in a new windowResumen external link opens in a new window

263. Barreiro TJ, Gemmel DJ. Noninvasive ventilation. Crit Care Clin. 2007;23:201-222.Resumen external link opens in a new window

264. Roberts CM, Brown JL, Reinhardt AK, et al. Non-invasive ventilation in chronic obstructive pulmonary disease: management of acute type 2 respiratory failure. Clin Med. 2008;8:517-521.Resumen external link opens in a new window

265. Smith TA, Davidson PM, Lam LT, et al. The use of non-invasive ventilation for the relief of dyspnoea in exacerbations of chronic obstructive pulmonary disease; a systematic review. Respirology. 2012;17:300-307.Resumen external link opens in a new window

266. Anton A, Guell R, Gomez J, et al. Predicting the result of noninvasive ventilation in severe acute exacerbations of patients with chronic airflow limitation. Chest. 2000;117:828-833.Resumen external link opens in a new window

267. Man WD, Soliman MG, Nikoletou D, et al. Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. Thorax. 2003;58:665-659.Resumen external link opens in a new window

268. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003;58:752-756.Texto completo external link opens in a new windowResumen external link opens in a new window

269. Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2008;149:869-878.Resumen external link opens in a new window

270. Langer D, Hendriks E, Burtin C, et al. A clinical practice guideline for physiotherapists treating patients with chronic obstructive pulmonary disease based on a systematic review of available evidence. Clin Rehabil. 2009;23:445-462.Resumen external link opens in a new window

271. Tang CY, Blackstock FC, Clarence M, et al. Early rehabilitation exercise program for inpatients during an acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. J Cardiopulm Rehabil Prev. 2012;32:163-169.Resumen external link opens in a new window

272. Bourbeau J, Julien M, Maltais F, Rouleau M, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003;163:585-591.Texto completo external link opens in a new windowResumen external link opens in a new window

273. Casas A, Troosters T, Garcia-Aymerich J, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J. 2006;28:123-130.Texto completo external link opens in a new windowResumen external link opens in a new window

274. Kuo CC, Lin CC, Lin SY, et al. Effects of self-regulation protocol on physiological and psychological measures in patients with chronic obstructive pulmonary disease. J Clin Nurs. 2013;22:2800-2811.Resumen external link opens in a new window

275. Fan VS, Gaziano M, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med. 2012;156:673-683.Resumen external link opens in a new window

276. Jeppesen E, Brurberg KG, Vist GE, et al. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(5):CD003573.Texto completo external link opens in a new windowResumen external link opens in a new window

277. McCurdy BR. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-65.Texto completo external link opens in a new windowResumen external link opens in a new window

278. Vitacca M, Bianchi L, Guerra A, et al. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur Respir J. 2009;33:411-418.Resumen external link opens in a new window

279. Pinnock H, Hanley J, McCloughan L, et al. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ. 2013;347:f6070.Texto completo external link opens in a new windowResumen external link opens in a new window

280. Patil SP, Krishnan JA, Lechtzin N, et al. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003;163:1180-1186.Texto completo external link opens in a new windowResumen external link opens in a new window

281. Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J. 2011;37:508-515.Texto completo external link opens in a new windowResumen external link opens in a new window

282. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest. 2000;117:662-671.Resumen external link opens in a new window

283. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005;26:234-241.Texto completo external link opens in a new windowResumen external link opens in a new window

284. Garcia-Aymerich J, Farrero E, Felez MA, et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58:100-105.Texto completo external link opens in a new windowResumen external link opens in a new window

285. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61:772-778.Texto completo external link opens in a new windowResumen external link opens in a new window

286. Piquet J, Chavaillon JM, David P, et al. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J. 2013;42:946-955.Texto completo external link opens in a new windowResumen external link opens in a new window

287. Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10:81-89.Texto completo external link opens in a new windowResumen external link opens in a new window

288. Almagro P, Soriano JB, Cabrera FJ, et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014;145:972-980.Texto completo external link opens in a new windowResumen external link opens in a new window

289. Sharma G, Kuo YF, Freeman JL, et al. Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:1664-1670.Texto completo external link opens in a new windowResumen external link opens in a new window

290. Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44:1156-1165.Texto completo external link opens in a new windowResumen external link opens in a new window

291. Mularski RA, Reinke LF, Carrieri-Kohlman V, et al. An official American Thoracic Society workshop report: assessment and palliative management of dyspnea crisis. Ann Am Thorac Soc. 2013;10:S98-S106.Texto completo external link opens in a new windowResumen external link opens in a new window

292. Gross N, Levin D. Primary care of the patient with chronic obstructive pulmonary disease-part 2: pharmacologic treatment across all stages of disease. Am J Med. 2008;121(suppl 7):S13-S24.Resumen external link opens in a new window

293. Sorensen SV, Baker T, Fleurence R, et al. Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis. Int J Tuberc Lung Dis. 2009;13:945-954.Resumen external link opens in a new window

294. Lodewijckx C, Sermeus W, Vanhaecht K, et al. Inhospital management of COPD exacerbations: a systematic review of the literature with regard to adherence to international guidelines. J Eval Clin Pract. 2009;15:1101-1110.Resumen external link opens in a new window

295. Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129:536-544.Resumen external link opens in a new window

296. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175:458-463.Resumen external link opens in a new window

297. Cindy Ng LW, Mackney J, Jenkins S, et al. Does exercise training change physical activity in people with COPD? A systematic review and meta-analysis. Chron Respir Dis. 2012;9:17-26.Resumen external link opens in a new window

298. COPD Working Group. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-75.Texto completo external link opens in a new windowResumen external link opens in a new window

299. Howcroft M, Walters EH, Wood-Baker R, Walters JA. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Dec 19;12:CD005074.Texto completo external link opens in a new windowResumen external link opens in a new window

300. Bucknall CE, Miller G, Lloyd SM, et al. Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ. 2012;344:e1060.Texto completo external link opens in a new windowResumen external link opens in a new window

301. Harrison SL, Janaudis-Ferreira T, Brooks D, et al. Self-management following an acute exacerbation of COPD: a systematic review. Chest. 2015;147:646-661.Resumen external link opens in a new window

302. McLean S, Nurmatov U, Liu JL, et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD007718.Texto completo external link opens in a new windowResumen external link opens in a new window

303. Franek J. Home telehealth for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-58.Texto completo external link opens in a new windowResumen external link opens in a new window